Pliant Therapeutics Inc
PLRX1.140USD
+0.050+4.59%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
70.05MValor de mercado
PerdaP/L TTM
Mais detalhes de Pliant Therapeutics Inc Empresa
Pliant Therapeutics, Inc. is a late-stage biotechnology company, which is focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.
Informações de Pliant Therapeutics Inc
Código da empresaPLRX
Nome da EmpresaPliant Therapeutics Inc
Data de listagemJun 03, 2020
CEOCoulie (Bernard J)
Número de funcionários171
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 03
Endereço331 Oyster Point Boulevard
CidadeSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94080
Telefone16504816770
Sitehttps://pliantrx.com/
Código da empresaPLRX
Data de listagemJun 03, 2020
CEOCoulie (Bernard J)
Executivos da empresa Pliant Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Bernard J. Coulie, M.D., Ph.D.
Dr. Bernard J. Coulie, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
616.26K
-89375.00%
Dr. Hoyoung Huh, M.D., Ph.D.
Dr. Hoyoung Huh, M.D., Ph.D.
Non-Executive Chairman of the Board, Lead Independent Director
Non-Executive Chairman of the Board, Lead Independent Director
99.76K
--
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
35.08K
--
Dr. John T. Curnutte, M.D., Ph.D.
Dr. John T. Curnutte, M.D., Ph.D.
Independent Director
Independent Director
29.28K
--
Ms. Lily Cheung
Ms. Lily Cheung
Chief Human Resources Officer
Chief Human Resources Officer
7.22K
-15713.00%
Dr. Eric Lefebvre, M.D.
Dr. Eric Lefebvre, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Keith Cummings, M.D.
Dr. Keith Cummings, M.D.
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Gayle Crowell
Ms. Gayle Crowell
Independent Director
Independent Director
--
--
Mr. Christopher Keenan
Mr. Christopher Keenan
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Mr. David E. I. Pyott, CBE
Mr. David E. I. Pyott, CBE
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Bernard J. Coulie, M.D., Ph.D.
Dr. Bernard J. Coulie, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
616.26K
-89375.00%
Dr. Hoyoung Huh, M.D., Ph.D.
Dr. Hoyoung Huh, M.D., Ph.D.
Non-Executive Chairman of the Board, Lead Independent Director
Non-Executive Chairman of the Board, Lead Independent Director
99.76K
--
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
35.08K
--
Dr. John T. Curnutte, M.D., Ph.D.
Dr. John T. Curnutte, M.D., Ph.D.
Independent Director
Independent Director
29.28K
--
Ms. Lily Cheung
Ms. Lily Cheung
Chief Human Resources Officer
Chief Human Resources Officer
7.22K
-15713.00%
Dr. Eric Lefebvre, M.D.
Dr. Eric Lefebvre, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Detalhamento da receita
FY2024
Os dados relevantes ainda não foram divulgados pela empresa.
Por RegiãoUSD
Nome
Receita
Proporção
United States
0.00
0.00%
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: qua, 4 de fev
Atualizado em: qua, 4 de fev
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Tang Capital Management, LLC
9.77%
Woodline Partners LP
7.33%
Point72 Asset Management, L.P.
7.06%
Morgan Stanley & Co. LLC
5.69%
Citadel Advisors LLC
4.94%
Outro
65.21%
Investidores
Investidores
Proporção
Tang Capital Management, LLC
9.77%
Woodline Partners LP
7.33%
Point72 Asset Management, L.P.
7.06%
Morgan Stanley & Co. LLC
5.69%
Citadel Advisors LLC
4.94%
Outro
65.21%
Tipos de investidores
Investidores
Proporção
Hedge Fund
39.23%
Investment Advisor
22.12%
Investment Advisor/Hedge Fund
12.57%
Research Firm
12.08%
Individual Investor
2.40%
Family Office
0.87%
Venture Capital
0.76%
Private Equity
0.04%
Bank and Trust
0.02%
Outro
9.92%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
358
52.26M
85.04%
-35.89M
2025Q3
356
52.49M
85.42%
-37.39M
2025Q2
374
62.63M
102.02%
-15.09M
2025Q1
390
63.45M
103.37%
-12.99M
2024Q4
392
71.13M
116.20%
-8.66M
2024Q3
388
69.61M
114.50%
-7.63M
2024Q2
375
69.93M
115.87%
-7.66M
2024Q1
371
73.36M
121.74%
-3.24M
2023Q4
362
70.03M
116.83%
-95.89K
2023Q3
356
64.13M
107.25%
-2.06M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Tang Capital Management, LLC
6.00M
9.77%
+3.45K
+0.06%
Sep 30, 2025
Woodline Partners LP
4.50M
7.33%
+2.16M
+91.81%
Sep 30, 2025
Point72 Asset Management, L.P.
4.34M
7.06%
+4.34M
--
Sep 30, 2025
Morgan Stanley & Co. LLC
3.50M
5.69%
+1.50M
+75.33%
Sep 30, 2025
Citadel Advisors LLC
2.34M
3.81%
-16.43K
-0.70%
Sep 30, 2025
Blue Owl Capital Holdings LP
2.97M
4.83%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
2.78M
4.52%
-226.41K
-7.54%
Sep 30, 2025
Acadian Asset Management LLC
2.37M
3.86%
+739.13K
+45.33%
Sep 30, 2025
J.P. Morgan Securities LLC
2.13M
3.46%
+171.21K
+8.76%
Sep 30, 2025
Two Sigma Investments, LP
1.86M
3.02%
+1.11M
+148.96%
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
iShares Micro-Cap ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Biotechnology ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
DFA Dimensional US Core Equity Market ETF
0%
Schwab U.S. Small-Cap ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Humankind US Stock ETF
0%
iShares Morningstar Small-Cap Value ETF
0%
Ver Mais
iShares Micro-Cap ETF
Proporção0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proporção0.01%
ProShares Ultra Nasdaq Biotechnology
Proporção0.01%
iShares Biotechnology ETF
Proporção0.01%
Invesco Nasdaq Biotechnology ETF
Proporção0.01%
DFA Dimensional US Core Equity Market ETF
Proporção0%
Schwab U.S. Small-Cap ETF
Proporção0%
Global X Russell 2000 Covered Call ETF
Proporção0%
Humankind US Stock ETF
Proporção0%
iShares Morningstar Small-Cap Value ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
